CTLA4 and cancer: These monoclonal antibodies are directed against the inhibitory immune receptors cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) and programmed death-1 (PD-1) and enhance the immune function of T-cells, thus mobilizing the body’s immune cells to selectively target cancer cells.